Actelion core earnings rise 9 percent, matching analyst poll

February 9, 2016 6:17 AM

2 0

Actelion core earnings rise 9 percent, matching analyst poll

ZURICH Actelion (ATLN.VX), Europe's largest biotechnology company, said on Tuesday that 2015 core earnings rose 9 percent, matching analyst forecasts, as the company was helped by rising sales of a new drug to treat a deadly heart-lung disease.

Core earnings were 814 million Swiss francs ($827.24 million), compared to analyst forecasts of 813 million francs. Product sales rose 4 percent to 2.042 billion francs, compared to the analyst forecast of 2.044 billion francs.

Also read: Hillary Clinton's Popular Vote Lead Over Donald Trump Now Exceeds 2.3 Million

Read more

To category page

Loading...